Articles - Page 53 of 101 - Drugs in Context

Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases

Valeria Nucera MD, Elisabetta Gerratana MD, Manuela Giallanza MD, Laura La Corte MD, Donatella Sangari MD, Fabiola Atzeni MD, PhD

Article Type

Review

Published

15 Jan 2021

This review focuses on cyclophosphamide due to its crucial role in the treatment of systemic sclerosis-related interstitial lung disease, particularly in the case of patients with progressive Interstitial lung diseases.

Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review

Giulia Cassone MD, PhD, Marco Sebastiani MD, Caterina Vacchi MD, PhD, Gian Luca Erre MD, Carlo Salvarani MD, Andreina Manfredi MD, PhD

Article Type

Review

Published

15 Jan 2021

This review describes the available data and recent advances on the effectiveness and safety of MMF for the treatment of ILD related to RD, including rheumatoid arthritis, systemic sclerosis, primary Sjögren syndrome, systemic lupus erythematosus, idiopathic inflammatory myopathies, undifferentiated connective tissue disease, interstitial pneumonia with autoimmune features and antineutrophil cytoplasmic antibody-associated vasculitis.

Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

Caterina Vacchi PhD, Andreina Manfredi MD, Giulia Cassone PhD, Gian Luca Erre MD, Carlo Salvarani MD, Marco Sebastiani MD

Article Type

Review

Published

15 Jan 2021

This article reviews the available efficacy and safety data on the use of rituximab in the treatment of rheumatic disease-related interstitial lung disease.

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications

Gian Luca Erre MD, PhD, Marco Sebastiani PhD, Andreina Manfredi MD, Elisabetta Gerratana MD, Fabiola Atzeni MD, Giuseppe Passiu MD, Arduino A Mangoni MD

Article Type

Review

Published

15 Jan 2021

This review discusses the experimental evidence and clinical trials investigating the efficacy and safety of antifibrotic drugs in patients with CTD-ILDs and the potential mechanisms of action involved.

Key policy and programmatic factors to improve influenza vaccination rates based on the experience from four high-performing countries

George Kassianos MD, Ashis Banerjee MD, Florence Baron-Papillon MD, Alan W Hampson MD, Janet E McElhaney MD, Allison McGeer MD, Thierry Rigoine de Fougerolles MSc, Mitch Rothholz MD, Holly Seale MD, Litjen J Tan MD, Angus Thomson PhD, Olivier Vitoux MSc

Article Type

Review

Published

05 Jan 2021

The aim of this analysis was to identify factors that have been instrumental in achieving a high influenza vaccine coverage rate (VCR) in the scope of four benchmark countries in order to provide an organised list of factors that could be used by countries with lower VCRs to help improve and strengthen their own VCRs.